Chardan Capital analyst Keay Nakae maintained Dyne Therapeutics with a Buy and lowered the price target from $50 to $38.

Dyne Therapeutics successfully closed a public offering, raising approximately $230.0 million in gross proceeds, which can be utilized for advancing its clinical and preclinical programs.

(RTTNews) - Dyne Therapeutics Inc. (DYN) announced the pricing of an underwritten public offering of about 24.24 million shares of its common stock at a public offering price of $8.25 per share.

Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July 7, Luca Issi from RBC Capital maintained a Buy rating on Dyne ...

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best biotech stocks to invest in now. On June 17, Dyne Therapeutics announced that the FDA granted Breakthrough Therapy Designation to DYNE-101 ...

Dyne Therapeutics Inc. (NASDAQ: DYN) is one of the best biotech stocks to invest in now. On June 17, Dyne Therapeutics announced that the FDA granted Breakthrough Therapy Designation to DYNE-101 ...